Black Taylor
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, United States.
Front Psychiatry. 2023 Sep 20;14:1159843. doi: 10.3389/fpsyt.2023.1159843. eCollection 2023.
Psychedelic-assisted treatment (PAT) for mental health is in renaissance. Psilocybin and MDMA stand near FDA approval, and US cities and states are decriminalizing or regulating the non-clinical use of psilocybin. However, neither FDA indications nor a regulated use model sufficiently address the complex needs and opportunities for an improved treatment of addiction. When paired with disability and social dispossession, addiction increasingly burdens informal care networks, public safety, and particularly healthcare systems. Stigma and mistreatment alienate people from opportunities for care and multiply the costs of providing care. This dynamic worsens socially determined resource limitations, enforcing stark ethical choices and perpetuating socioeconomic inequities, isolation, mental illness, medical illness, overdose, suicide, and violence. In order for psychedelic treatments to achieve their greatest utility to population health, we must intentionally develop regulatory, clinical, and payment systems supporting clinical research, rigorous safety monitoring, and implementation to address these immense needs and reduce the barriers to engagement for those who now bear the costs, including those who work at the front lines of addiction care. To achieve full fruition, I advocate for a collaborative approach, built from within networks of mutual social support but linked and accountable to public institutions charged with the equitable dissemination of these therapies for the greatest social and health equities. Rather than relegating PAT to the needs of the commercially insured or wellness markets, this is the moment to learn from ancient traditions of ritualized sacramental use, organized around faith in our mutual dependency and accountability, and to capture an opportunity to improve population health and equity. To miss this opportunity is to accept the status quo in the midst of a growing emergency, for lack of moral vision and intention to change our habits.
用于心理健康的迷幻剂辅助治疗(PAT)正在复兴。裸盖菇素和摇头丸已接近获得美国食品药品监督管理局(FDA)的批准,而且美国的一些城市和州正在将裸盖菇素的非临床使用合法化或进行规范管理。然而,无论是FDA的适应症还是规范的使用模式,都不足以充分满足改善成瘾治疗的复杂需求和机遇。成瘾与残疾和社会剥夺相伴时,会给非正式护理网络、公共安全,尤其是医疗保健系统带来越来越大的负担。污名化和虐待使人们失去获得护理的机会,并增加了提供护理的成本。这种动态变化加剧了社会决定的资源限制,迫使人们做出严峻的道德选择,并使社会经济不平等、孤立、精神疾病、身体疾病、药物过量、自杀和暴力长期存在。为了使迷幻剂治疗对人群健康发挥最大效用,我们必须有意地建立监管、临床和支付系统,以支持临床研究、严格的安全监测和实施,从而满足这些巨大需求,并减少那些目前承担成本的人(包括成瘾护理一线工作人员)参与治疗的障碍。为了实现全面发展,我主张采取一种合作方法,这种方法建立在相互社会支持网络内部,但与负责公平传播这些疗法以实现最大社会和健康公平的公共机构相联系并对其负责。不应将PAT局限于商业保险或健康市场的需求,现在是时候借鉴围绕对我们相互依存和责任的信念而组织的仪式性圣礼使用的古老传统,并抓住机会改善人群健康和公平。错过这个机会就是在日益严重的紧急情况下接受现状,因为缺乏道德愿景和改变我们习惯的意愿。